Department of Surgery, Duke University School of Medicine, Durham, NC, USA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.
All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 20I/501Y.V1), contains eight spike mutations with potential to impact antibody therapy, vaccine efficacy, and risk of reinfection. Here, we show that B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels (∼sim;2-fold), by serum samples from convalescent individuals and recipients of an mRNA vaccine (mRNA-1273, Moderna) and a protein nanoparticle vaccine (NVX-CoV2373, Novavax). A subset of monoclonal antibodies to the receptor binding domain (RBD) of spike are less effective against the variant, while others are largely unaffected. These findings indicate that variant B.1.1.7 is unlikely to be a major concern for current vaccines or for an increased risk of reinfection.
所有当前用于 COVID-19 的疫苗都利用了 SARS-CoV-2 的原始刺突蛋白，旨在产生保护性的中和抗体。最近出现的并迅速传播的几种携带多个刺突突变的 SARS-CoV-2 变体引起了人们对可能的免疫逃逸的担忧。一种变体最初在英国被发现（B.1.1.7，也称为 20I/501Y.V1），它包含八个可能影响抗体治疗、疫苗效力和再感染风险的刺突突变。在这里，我们表明 B.1.1.7 仍然对恢复期个体和 mRNA 疫苗（mRNA-1273，Moderna）和蛋白纳米颗粒疫苗（NVX-CoV2373，Novavax）的血清样本敏感，但中和水平适度降低（~约 2 倍）。针对刺突受体结合域（RBD）的一组单克隆抗体对该变体的效果较差，而其他抗体则基本不受影响。这些发现表明，变体 B.1.1.7 不太可能成为当前疫苗或再感染风险增加的主要关注点。
Zotero 插件
